Company search
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Data as at: 24/04/2024
In
Objective
To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
AIC sector
Management group
Frostrow Capital
Company website
Launch date
28/04/1995
March
Domicile
United Kingdom
Fund manager
Sven H. Borho, Trevor M. Polischuk
Dividend frequency
Semi-Annually
Wind-up provisions
Continuation vote at every fifth AGM, the next of which will be in 2024.
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 1,821.41 | 2,034.15 | 336.50 | 375.20 | -10.31 | 1 | 0.92 | Jun, Nov | 0.8 (31/03/2023) |
Scroll
Dividends
Dividends declared in last 12 months
| Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
|---|---|---|---|---|
| 23/11/2023 | 11/01/2024 | 0.700 | No | 2024 |
| 08/06/2023 | 26/07/2023 | 2.400 | No | 2023 |
Scroll
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| Worldwide Healthcare Trust | Share price total return | 3.9 | -10.1 | 35.2 | 194.5 |
| Biotechnology & Healthcare AIC sector | Share price total return | -1.1 | -20.5 | 3.6 | 130.2 |
Scroll
Share structure
Number of shares
541,280,736
60,384,464
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 1,766,287 | 30,228,413 | 322,156,136 | 1,374,451,726 |
| Average | N/A | 1,523,560 | 1,272,590 | 1,089,580 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 5.94 | 100.08 | 1,013.26 | 4,516.96 |
| Average | N/A | 5.05 | 4.00 | 3.58 |
Scroll
Trading details
Top holdings
Data as at : 31/12/2023
| Investment | % of total assets |
|---|---|
| Eli Lilly and Co | 7.3 |
| Novo Nordisk A/S Class B | 6.3 |
| AstraZeneca PLC | 6.0 |
| Boston Scientific Corp | 6.0 |
| Intuitive Surgical Inc | 5.3 |
| Biogen Inc | 4.9 |
| Merck & Co Inc | 3.8 |
| Biomarin Pharmaceutical Inc | 3.7 |
| Daiichi Sankyo Co Ltd | 3.4 |
| Other Assets And Liabilities | -3.0 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
